目的 系統(tǒng)評價吉西他濱聯(lián)合替吉奧治療晚期胰腺癌的有效性和安全性，為臨床用藥治療提供科學(xué)依據(jù)。方法 計算機檢索Cochrane圖書館臨床對照試驗資料庫、EMBASE、PubMed、中國生物醫(yī)學(xué)文獻數(shù)據(jù)庫（CBM）、中國期刊全文數(shù)據(jù)庫（CNKI）、維普數(shù)據(jù)庫（VIP）、萬方科技等數(shù)據(jù)庫中關(guān)于吉西他濱聯(lián)合替吉奧治療晚期胰腺癌臨床隨機對照試驗（RCT），檢索時間均從各數(shù)據(jù)庫創(chuàng)建至2019年12月。由兩名評價員獨立評價文獻質(zhì)量、提取資料并交叉核對，并進行方法學(xué)質(zhì)量評價，采用RevMan 5.2的軟件進行Meta-分析。結(jié)果 共納入23篇RCTs，共1 817例患者，其中治療組920例、對照組897例。Meta-分析結(jié)果顯示：應(yīng)用吉西他濱聯(lián)合替吉奧組總有效率[RR=1.76，95% CI（1.51，2.04），P<0.000 01]和臨床獲益率[RR=1.40，95% CI（1.30，1.50），P<0.000 01]與對照組相比有顯著性差異；在安全性方面，治療組不良反應(yīng)發(fā)生危險度高于對照組。結(jié)論 基于現(xiàn)有臨床證據(jù)，吉西他濱聯(lián)合替吉奧在治療晚期胰腺癌方面均較對照組療效更為顯著，是一種較為理想的用藥方案。

Objective To systematically evaluate efficacy and safety of gemcitabine combined with tegafur for advanced pancreatic cancer, for which to provide scientific proofs for clinical decision making. Methods The databases including:The Cochrane Library、EMBASE、PubMed、CNKI、CBM、VIP、Wanfang Data were searched from the inception to Dec 2019 to collect the randomized controlled trials (RCTs) related to the safety and efficacy of gemcitabine combination with tegafur versus monotherapy for the treatment of advanced pancreatic cancer. Quality assessment and data extraction were conducted by two reviewers independently. Disagreement was resolved through discussion. and data analyses were performed with RevMan 5.2 software. Results A total of 23 articles were included, including 1 817 patients. There were 920 patients in treatment groups and 897 patients in the control group. The Meta-analysis results showed that, In terms of validity, compared with the control group, the total effective rate and clinical benefit rate were significantly different in gemcitabine combined with tegafur group, the total effective rate[RR=1.76, 95%CI(1.51, 2.04), P<0.000 01] and clinical benefit rate[RR=1.40, 95%CI(1.30, 1.50), P<0.000 01], In terms of safety, The results of toxic side effects were obviously higher than those in gemcitabine monotherapy. Conclusion Based on the present clinical evidence, the meta-analysis results indicate that the treatment efficacy of gemcitabine combined with tegafur group is better than control group on treating advanced pancreatic cancer, which is a standard treatment of advanced pancreatic cancer.

979.1

戰(zhàn)略支援部隊特色醫(yī)學(xué)中心醫(yī)藥衛(wèi)生基礎(chǔ)研究探索課題（19ZX63，19ZX17）